Ainuovirine/Lamivudine/Tenofovir Disoproxil Fumarate

艾诺米替

Report date: 2025/03/31 10:39:21
NME

Base Information

Drug NameAinuovirine/Lamivudine/Tenofovir Disoproxil Fumarate
Drug Alias Name复方ACC007艾诺米替艾诺韦林/拉米夫定/富马酸替诺福韦二吡呋酯复邦德ACC-008
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHuman immunodeficiency virus type 1 reverse transcriptase inhibitorsReverse transcriptase inhibitorsHBV DNA Polymerase inhibitors
TargetsReverse transcriptaseHuman immunodeficiency virus type 1 reverse transcriptaseHBV DNA Polymerase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryMainland China
Original Approved Date2023/01/04
Country/TerritoryMainland China
CombinationsYes AinuovirineLamivudineTenofovir Disoproxil Fumarate
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Aidea Pharmaceutical Group Co LtdNanjing Accelas Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJiangsu Aidea Pharmaceutical Group Co Ltd
Inactive CompaniesNanjing Accelas Pharmaceutical Co Ltd
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeJ05AG
Related LinksN/A